FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
2024 Q3
2024 Q2
2024 Q1
2023 Q4
0
100k
0
1.63M
0
475k
360k
298k
0
-375k
-360k
1.34M
46.8M
161M
73.47M
89.63M
38.89M
67.63M
63.59M
81.84M
7.9M
93.37M
9.87M
7.79M
0
0
-104k
-46k
7.9M
93.37M
9.97M
7.83M
0
0
-59k
-158k
-46.8M
-160.9M
-73.83M
-88.29M
2.93M
2.02B
-4.88M
-3.69M
-43.86M
1.86B
-78.71M
-91.97M
0
2k
316.72k
-4k
-43.86M
1.86B
-78.71M
-93.6M
-2.84
128.35
-1.44
-1.73
-2.84
125.48
-1.44
-1.73
15.47M
14.48M
54.55M
54.03M
15.47M
14.81M
54.55M
54.03M
-46.8M
1.86B
-73.47M
-87.99M
2024 Q3
2024 Q2
2024 Q1
2023 Q4
-14.4M
-692.44M
-613.73M
-520.13M
-43.86M
1.86B
-78.71M
-93.6M
0
0
0
0
0
0
0
0
-58.27M
-14.4M
-692.44M
-613.73M
-43.86M
678.04M
-78.71M
-93.6M
2024 Q3
2024 Q2
2024 Q1
2023 Q4
8.4M
9.62M
9.45M
9.37M
760k
476k
360k
298k
-247k
-1.22M
-1.12M
-3.44M
7.89M
10.36M
10.21M
12.52M
2024 Q3
2024 Q2
2024 Q1
2023 Q4
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.